Spindle cell carcinoma of the breast managed with neoadjuvant AIM: A case report
Spindle cell carcinoma (SpC), also known as metaplastic carcinoma—spindle cell type, is a subtype of metaplastic carcinoma. Metaplastic carcinomas of the breast are rare but are thought to be more aggressive than invasive ductal carcinomas. Due to their rarity, there are few randomized trials that c...
Saved in:
Published in | Rare tumors Vol. 12; p. 2036361320977021 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
London, England
SAGE Publications
2020
Sage Publications Ltd SAGE Publishing |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Spindle cell carcinoma (SpC), also known as metaplastic carcinoma—spindle cell type, is a subtype of metaplastic carcinoma. Metaplastic carcinomas of the breast are rare but are thought to be more aggressive than invasive ductal carcinomas. Due to their rarity, there are few randomized trials that can inform any standardized approaches to treatment. Treatment is instead extrapolated from other types of breast cancer or metaplastic carcinomas of different locations. Here we present the first known case report of a patient with spindle cell carcinoma of the breast successfully treated with a standard sarcoma neoadjuvant regimen of doxorubicin, ifosfamide, and mesna (AIM) that resulted in >99% necrosis of the tumor and negative margins at the time of resection. |
---|---|
ISSN: | 2036-3613 2036-3605 2036-3613 |
DOI: | 10.1177/2036361320977021 |